ODAC unanimously upholds MRD as early endpoint across all settings in multiple myeloma – The Cancer Letter
In a unanimous vote, the FDA Oncologic Drugs Advisory Committee advised the agency to accept the metric of “minimal residual disease,” or MRD, as a basis for accelerated approvals of therapies in all settings of multiple myeloma. To access this subscriber-only content please log in or renew your subscription.Looking for IP Login? Our IP Login […]